ArticleGlobal ecology and conservation2022
Impacts of the SARS-CoV-2 pandemic on the global demand for exotic pets: An expert elicitation approach.
Article in Global ecology and conservation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 8 citations in OpenAlex.
- A One Health Perspective on Multidrug Resistance Amongst Iberian Exotic Pet Owners.Veterinary sciences · 2025Article
- Future trajectory of SARS-CoV-2: Constant spillover back and forth between humans and animals.Virus research · 2023Review
- Potential for invasion of traded birds under climate and land-cover change.Global change biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The SARS-CoV-2 pandemic has caused immense social and economic costs worldwide. Most experts endorse the view that the virus has a zoonotic origin with the final spillover being associated with wildlife trade. Besides human consumption, wild animals are also extensively traded as pets. Information on zoonotic diseases has been reported to reduce consumer demand for exotic pets. We conducted a global survey and collected 162 responses from international experts on exotic pet trade (traders, academics, NGOs, enforcement entities) to understand how the legal and illegal trade of exotic pets is expected to be affected by the ongoing coronavirus pandemic. Our results suggest that legal purchase of exotic pets is perceived as decreasing during the first pandemic wave due to: lower availability of animals for trade, suppliers' inability to reach consumers and social distancing measures. The general perception is that in the future (i.e., next five years), both demand and supply of legally traded exotic pets are expected to either remain unchanged or decrease only temporarily. The consumer demand for illegal exotic pets is also expected to remain unchanged following the outbreak. The top two challenges reported by respondents, when considering the consequences of the pandemic for the exotic pet trade, are inadequate enforcement of national regulations and increased illegal trade. Our results suggest that the negative consequences of a zoonotic outbreak may not dissuade consumers of exotic pets. Worldwide, the transit/storing conditions and lack of health screenings of traded live animals are conducive to spreading diseases. Consumer demand is a key driver of trade, and enforcement of trade regulations will remain challenging, unless factors driving consumer demand are adequately incorporated in problem-solving frameworks. We emphasize the complexity of trade dynamics and the need to go beyond bans on wildlife trade. Stronger law enforcement, implemented along with initiatives dissuading consumption of wild exotic pets, are essential to sustainably satisfy the market demand.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.